Celularity Announces Filing of Form 10-Q Quarterly Reports for the First Quarter and the Second Quarter 2025, Confirmation of Nasdaq Listing Rule 5250(c)(1) Compliance
1. Celularity regained Nasdaq compliance by filing 10-Q reports. 2. The company retired $32 million in senior secured debt. 3. Wound care product sales pressure impacted cash collections. 4. Celularity aims to fuel growth through new working capital facilities. 5. The firm is advancing three late-stage 510(k) pipeline products.